Shots:

• The P-IIIb STASEY study evaluates the safety of Hemlibra (qw for ~2 yrs.) in 193 patients with hemophilia A with factor VIII inhibitors. The results of the study are consistent with a P- III HAVEN program
• The results from the final analysis of a P-IIIb STASEY study showed no new thrombotic microangiopathy or thrombotic SAEs & no new safety signals were observed. The therapy showed effective bleed control with 82.6% of patients achieving zero treated bleeds
• Additionally- the study reinforced that Hemlibra is associated with a low incidence of ADA development. The therapy is approved to treat patients with hemophilia A with/out factor VIII inhibitor in 100+/80+ countries respectively

  Ref: Business Wire | Image: Center for Health Journalism